IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells.

Publication Title

Nat Commun

Authors

Olivier Fesneau, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.Follow
Kimberly Samson, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.Follow
Wesley K Rosales, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.Follow
Bretton Jones, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Tarsem Moudgil, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.Follow
Bernard A Fox, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.Follow
Venkatesh Rajamanickam, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.Follow
Thomas Duhen, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.Follow

Document Type

Article

Publication Date

11-18-2024

Keywords

Humans; NK Cell Lectin-Like Receptor Subfamily C; CD8-Positive T-Lymphocytes; Interleukin-12; Colorectal Neoplasms; Lymphocytes, Tumor-Infiltrating; Antigens, CD; Squamous Cell Carcinoma of Head and Neck; Integrin alpha Chains; Receptors, Antigen, T-Cell; HLA-E Antigens; Head and Neck Neoplasms; Cell Differentiation; Apyrase; oregon; portland; chiles

Abstract

Blockade of NKG2A/HLA-E interaction is a promising strategy to unleash the anti-tumor response. Yet the role of NKG2A

Area of Special Interest

Cancer

Area of Special Interest

Digestive Health

Specialty/Research Institute

Oncology

Specialty/Research Institute

Dermatology

DOI

10.1038/s41467-024-54420-w